Stomach Cancer Treatment Market

SKU: DMPH2190 | Last Updated On: Nov 02 2022 | Available Formats

>Stomach Cancer Treatment Market Expected to reach a high CAGR of 5.2% By 2029: DataM Intelligence

Stomach Cancer Treatment Market is segmented By Treatment Type (Surgery, Endoscopic Mucosal Resection, Chemotherapy, Radiation Therapy, Chemoradiation, Targeted Therapy, Immunotherapy), By Distribution Channel (Hospitals and Clinics, Ambulatory Surgical Centers, Cancer Research Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Stomach Cancer Treatment Market size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.2% during the forecast period (2022-2029).

Stomach Cancer Treatment Market - Strategic Insights

Metrics

Details

Market CAGR

5.2%

Segments Covered

By Treatment Type, By Distribution Channel,and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Stomach cancer is a disease in which malignant (cancer) cells form in the stomach lining. Stomach cancer usually begins in the mucus-producing cells that line the stomach. This type of cancer is called gastric cancer or adenocarcinoma. Age, diet, and stomach disease can affect the risk of developing stomach cancer. Symptoms of stomach cancer include indigestion and stomach discomfort or pain. This type of cancer is difficult to diagnose because most people typically do not show signs in the earlier stages. Since stomach cancer usually does not cause any early symptoms, it often goes undiagnosed until after it spreads to other body parts. According to the National Cancer Institute, 1.8% of the deaths caused by cancer are due to stomach cancer.

Market Dynamics

The stomach cancer treatment market growth is driven by several factors, such as increased stomach cancer cases and the approval of new drugs.

The high prevalence of gastric cancer is driving the global market growth.

Stomach cancer remains one of the most common and deadly cancers worldwide, especially among older males. Based on the GLOBOCAN database for 2020, Gastric cancer was the 5th most common cancer and the 4th leading cause of cancer death worldwide. Globally, 1.1 million people were diagnosed with the disease, and 770,000 subsequent deaths occurred in 2020; if current rates remain stable, future projections indicate that 1.8 million cases and 1.3 million deaths are expected to occur in 2040, which is 66% and 71% higher than that estimated in 2020. The incidence and mortality are highly variable by region and highly dependent on diet and Helicobacter pylori infection. Over one million cases of stomach cancer are diagnosed worldwide each year. Stomach cancer is more prevalent in males. In developed countries, stomach cancer is two times more likely to be diagnosed in males than in females. In five countries worldwide, stomach cancer has the highest incidence among all cancers for males. According to the European Society for Medical Oncology, stomach cancer is no longer just the cancer of the elderly; globally, the rate of stomach cancer in younger people has increased substantially.

The treatment side effects are expected to hinder global Stomach Cancer Treatment market growth.

The primary factors hampering the growth of the stomach cancer drugs market are the serious side effects caused by the drugs, such as nausea and vomiting, loss of appetite and weight loss, fatigue, diarrhea, hair loss, sore mouth, hand-foot syndrome, low blood cell counts, blood clots (Deep Vein Thrombosis), nervous system damage, and heart damage in patients undergoing treatment for stomach cancer.

Industry analysis.

The global stomach cancer treatment market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

Segment Analysis

Chemotherapy is assumed to command the stomach cancer treatment market throughout the forecast period (2022-2029).

Chemotherapy is expected to be the dominant market shareholder over the forecast period (2022-2029) as chemotherapy helps shrink cancer or slow its growth, relieving symptoms for some patients and helping them live longer. Gastric cancer is usually diagnosed at later stages when the cancer is spread to other body parts; chemotherapy is the most effective treatment in later stages. Chemotherapy uses anti-cancer drugs injected into a vein or given by mouth as pills. These drugs enter the bloodstream and reach all body areas, making this treatment useful for cancer spreading to organs beyond where it started. Chemo is also given before surgery for stomach cancer and is known as neoadjuvant treatment, which can shrink the tumor and possibly make surgery easier. It may also help prevent cancer and help patients live longer. Chemo may be given after surgery to remove cancer and is called adjuvant treatment. The goal of adjuvant chemo is to kill cancer cells that may have been left behind but are too small to see. For stomach cancer, chemo is often given with radiation therapy after surgery. This combination is called chemoradiation. which may be especially helpful for cancers that cannot be entirely removed by surgery. Most chemotherapy drugs used to treat stomach cancer include Capecitabine (Xeloda), Carboplatin, Cisplatin, Docetaxel (Taxotere) and many more.

Geographical Analysis

The Asia Pacific region holds the largest market share of the global Stomach Cancer Treatment market.

The Asia Pacific has dominated the stomach cancer treatment market in 2021 and is estimated to hold the largest market size over the forecast period (2022-209), owing to an increased prevalence of stomach cancer, a highly aware population, advanced healthcare infrastructure, and favorable government initiatives. According to Global Cancer Observatory WHO, in 2020, there were around 656 349 new cases with 435 211 deaths; in South-Eastern Asia, there were 39 763new cases, and 32 814 deaths occurred; in South-Central Asia, around 102 676 new cases were found with 89 595 deaths and Western Asia observed 21 156 new cases with 17 586 deaths; making Asia Pacific region with the highest stomach cancer prevalence. Furthermore, according to the Roswell Park Comprehensive Cancer Center, Asian countries, including Korea, Japan and China, experience disproportionately high rates of stomach cancer, possibly due to high infection rates with Helicobacter pylori, also known as H. pylori and the increased consumption of salted and smoked foods.

Competitive Landscape

Some of the major key players in the market are Bristol-Myers Squibb, Celltrion, Eli Lilly and Company, Roche, GlaxoSmithKline Plc, Imugene, Novartis AG, Merck, Taiho Oncology and Pfizer. Due to new product approvals, mergers, collaborations, and acquisitions, Merck holds a leadership position in the stomach cancer treatment market. The key players are adopting various growth strategies such as new product launches, mergers & acquisitions, partnerships, and collaborations and increasing research and development and high investment, which are contributing to the growth of the stomach cancer treatment market globally. For instance, in May 2022, Pfizer agreed to acquire Biohaven. For instance, on 04 May 2022, Bristol Myers Squibb received European Commission approval for Opdivo (nivolumab) with chemotherapy as a first-line treatment for patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC). Also, on December 22, 2021, Novartis acquired Gyroscope Therapeutics.

Bristol-Myers Squibb Company

Overview:

The Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York City. BMS is a leading pharmaceutical company and has consistently ranked among the largest U.S. corporations. For fiscal 2021, it had total revenue of $46.4 billion.

Product Portfolio:

 The product portfolio of Bristol-Myers Squibb Company for stomach cancer treatment contains Opdivo (nivolumab).

The global stomach cancer treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Frequently Asked Questions

What is the Projected CAGR value of the Stomach Cancer Treatment Market?

Stomach Cancer Treatment Market is expected to grow at a CAGR of 5.2% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Stomach Cancer Treatment Market during 2022-2029.

Which is the fastest growing region in the Stomach Cancer Treatment Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period.

Trending Topics

Cancer Stem Cell Therapy Market

Cancer CDK Inhibitors Market

Cancer Biopsies Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest